Sōlaria Biō
2017
- Catherine Balsam-Schwaber, CEO
- Eric Schott, PhD, Co-Founder and COO
Cambridge, MA
- Increased availability, accessibility, and/or affordability of healthier foods and nutrition-based solutions
-
Good Health and Well-Being
-
Industry, Innovation and Infrastructure
-
Responsible Consumption and Production
The company has built a best-in-class strain catalog of bacterial and fungal diversity isolated from fresh fruits and vegetables, a database of their genomes, and a computational platform to mine them to develop medical foods. Sōlaria Biō incorporates the highest level of scientific rigor into every aspect of its process, validating products in robust randomized, placebo-controlled clinical food trials to create novel solutions for managing inflammatory diseases.
Insights
News
The Promise of Novel Synbiotic Medical Foods for Age-Related Inflammatory Conditions
Journa Unveils Bondia, a Daily Synbiotic Medical Food
Footnotes
S2G North Star Interim Outcomes reflect areas of strategic alignment with our long-term impact goals. These outcomes are intended to illustrate the types of non-financial progress S2G seeks to support across its portfolio and do not represent company-specific metrics or outcomes. They are not a reflection of investment performance, actual or realized returns, or future financial results.
UN Sustainable Development Goal (SDG) alignment has been obtained from portfolio companies, internally collected data by S2G and/or sources outside S2G, and could prove to be incomplete or inaccurate and is current only as of July 31, 2026. S2G makes no representations as to the accuracy or completeness of the information obtained from such portfolio companies and/or sources and neither S2G nor any of its affiliates takes any responsibility for, and has not independently verified, any such information.